GlobalRPh Renal Dosing Masterv6.6
Evidence addition

Amphotericin B liposomal (AmBisome)

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons

AmBisome

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

Amphotericin B liposomal (AmBisome) - selected U.S. labeling

Product / population
Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Renal measure
Qualitative renal/PK evidence; no label CrCl-based reduction table.
Labeled basic dosing

Labeled adult initial doses: empirical therapy 3 mg/kg IV daily; systemic fungal infection 3-5 mg/kg daily; HIV-associated cryptococcal meningitis 6 mg/kg daily. Infuse initially over about 120 minutes; approximately 60 minutes may be used when tolerated.

Renal information and dialysis

Renal-impairment pharmacokinetics have not been studied, although patients with pre-existing dysfunction received treatment. No numeric CrCl reduction is provided. Hemodialysis/peritoneal dialysis do not appear to materially increase elimination.

Selected warnings and limits

Monitor renal function and electrolytes. This product cannot be substituted milligram-for-milligram for another amphotericin formulation. Use only its own preparation instructions.

Source revision: Label revision date not separately recorded; retrieval date is not the revision date. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a

Scope: Selected dosing/renal sections read; concise local summary, not full prescribing information. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Official product label

Amphotericin B liposomal (AmBisome) - selected U.S. labeling

Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.

Renal method: Qualitative renal/PK evidence; no label CrCl-based reduction table.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF AmBisome - renal and dialysis protocols

Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.

Renal method: No renal dose reduction; source-specific weight convention
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Official source

Amphotericin B liposomal (AmBisome) - selected U.S. labeling

Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.

Method: Qualitative renal/PK evidence; no label CrCl-based reduction table.

Renal information and dialysisRead this complete source summary
Professional source

UCSF AmBisome - renal and dialysis protocols

Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.

Method: No renal dose reduction; source-specific weight convention

Source-specific renal protocolRead this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAmphotericin B liposomal (AmBisome) - selected U.S. labelingUCSF AmBisome - renal and dialysis protocols
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a

Product and population scope

Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.

RDM31-amphotericin-b-liposomal-scope · Source section: Editorial scope tied to selected U.S. labelRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Amphotericin B liposomal (AmBisome) - selected U.S. labeling

Open original reference

Open / share this exact local source

U.S. product labeling / DailyMed · Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.

Renal method: Qualitative renal/PK evidence; no label CrCl-based reduction table.
Source date: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05

Selected dosing/renal sections read; concise local summary, not full prescribing information.

Labeled basic dosing

Labeled adult initial doses: empirical therapy 3 mg/kg IV daily; systemic fungal infection 3-5 mg/kg daily; HIV-associated cryptococcal meningitis 6 mg/kg daily. Infuse initially over about 120 minutes; approximately 60 minutes may be used when tolerated.

RDM31-amphotericin-b-liposomal-label-dose · Source locator: Dosage and Administration

Renal information and dialysis

Renal-impairment pharmacokinetics have not been studied, although patients with pre-existing dysfunction received treatment. No numeric CrCl reduction is provided. Hemodialysis/peritoneal dialysis do not appear to materially increase elimination.

RDM31-amphotericin-b-liposomal-label-renal · Source locator: Clinical Pharmacology: Special Populations; Overdosage

Selected warnings and limits

Monitor renal function and electrolytes. This product cannot be substituted milligram-for-milligram for another amphotericin formulation. Use only its own preparation instructions.

RDM31-amphotericin-b-liposomal-label-limits · Source locator: Precautions: Laboratory Tests; Dosage and Administration

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a
Retrieved
2026-09-05
DailyMed Set ID
f7be6506-4d20-401e-a0ff-02ad7c33158a
Renal-function method
Qualitative renal/PK evidence; no label CrCl-based reduction table.
Source date/version
Label revision date not separately recorded; retrieval date is not the revision date.
Hash meaning
SHA-256 identifies this local summary, not original SPL XML or label PDF.
Local summary SHA-256
75ba65d98cd36b11e4933e15015ef7e21bf7a96f4d481b8c5410682b2c3d2066
Separate professional-source layer

University and professional protocols

Professional

UCSF AmBisome - renal and dialysis protocols

Open original reference

Open / share this exact local source

University of California San Francisco (UCSF) · Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.

Renal method: No renal dose reduction; source-specific weight convention
Source date: Revision date not stated on the reviewed page.
Retrieved: 2026-09-05

Separate professional-source protocol; not automatically equivalent to product labeling.

Source-specific renal protocol

UCSF uses 4 mg/kg IV every 24 hours with flucytosine for cryptococcal meningitis, 5 mg/kg daily for invasive fungal infection, and 3 mg/kg daily for heme/BMT mold prophylaxis. These schedules are also listed for IHD and continuous dialysis. Monitor creatinine/electrolytes. Use total body weight unless it exceeds 120% of ideal weight, when adjusted weight is used.

RDM31-amphotericin-b-liposomal-prof-1 · Source locator: Dosing Weights; adult and dialysis tables; Dialysis Notes

Source-specific limits

The cryptococcal 4 mg/kg combination regimen differs from the label's 6 mg/kg regimen; preserve the entire selected treatment plan. The source's optional saline hydration requires assessment of fluid tolerance; it is not an instruction to mix saline into AmBisome.

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ambisome-liposomal-amphotericin-b
Retrieved
2026-09-05
Renal-function method
No renal dose reduction; source-specific weight convention
Source date/version
Revision date not stated on the reviewed page.
Hash meaning
SHA-256 identifies the local paraphrase, not original source bytes.
Local summary SHA-256
2c61f9bcc77b3a4838965b0e224beef13a2a4695bd01d2c20c4023a5a2fa8bba

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7be6506-4d20-401e-a0ff-02ad7c33158a
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
fc75cabca760a591e92fc68aabdcff3e52858e34dbd18f5fe3ce4b0349fb37e2
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report